Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.59 |
| ▸ | IKBKB | O14920 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444360 | 0.92 | HDAC8 (0.58) | HDAC8HDAC6HDAC1HDAC7HDAC9 | |
| SCHEMBL444459 | 0.91 | HDAC8 (0.60) | HDAC8HDAC6HDAC1HDAC7HDAC9 | |
| SCHEMBL444068 | 0.91 | HDAC8 (0.59) | HDAC8HDAC6HDAC1HDAC7HDAC9 | |
| SCHEMBL443814 | 0.91 | HDAC8 (0.59) | HDAC8HDAC6HDAC1HDAC7HDAC9 | |
| SCHEMBL442449 | 0.90 | HDAC8 (0.63) | HDAC8HDAC6 | |
| SCHEMBL443034 | 0.90 | HDAC8 (0.62) | HDAC8HDAC6HDAC1HDAC7HDAC9 | |
| SCHEMBL444784 | 0.89 | HDAC8 (0.61) | HDAC8HDAC6HDAC1HDAC7HDAC9 | |
| SCHEMBL444385 | 0.88 | HDAC8 (0.62) | HDAC8HDAC6HDAC1HDAC7HDAC9 | |
| SCHEMBL443074 | 0.88 | HDAC8 (0.62) | HDAC8HDAC6IKBKBHDAC1HDAC7 | |
| SCHEMBL447618 | 0.88 | HDAC8 (0.60) | HDAC8HDAC6HDAC1HDAC7HDAC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613775-B1 | N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | claimed |
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | claimed |
| EP-2613775-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | claimed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | claimed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | claimed |
| EP-2613775-B1 | N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2613775-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | HNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRAS | HDAC8 304/4885HDAC6 41/4885IKBKB 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.